evt_81d7eb61-5afb-5af9-a6ee-f0d1b9880db2Johnson & Johnson
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
multiple myeloma
evd_2e28f506-4e40-55a0-bab9-2bfd83423db5, evd_45668a12-65d5-50ff-9f8f-32bd99cd3e00, evd_5efbf396-e598-50b5-9502-9ef47c90199d, evd_6d5875f0-a119-58c8-a135-5ed6b99eedbd, evd_8f041091-4876-5456-9906-15de65d2994e, evd_b24182a2-815e-5503-bbf2-e9ade231dc60, evd_c0b165ff-f3e9-5910-b373-6c0c2f2adfef, evd_c33e32f6-134d-5efe-8536-06ac7c28b7ea, evd_ec9babc1-f0a9-52c4-9d6f-014553576f04, evd_fefffb30-d08e-5e56-a562-4707bc94da1bfact_215d0c20-1ec9-5b35-a53c-32d2711dcd7d, fact_21f144a4-3774-5cfe-8eff-f2349bec5daf, fact_6a289db6-64de-5916-9141-9a47a7d76413, fact_7a849c8f-3ab2-58d1-bad6-6d2401a72569, fact_afef352a-c0a9-5353-99b4-f61d21581347rel_51ace27e-6045-5bbf-a5cd-f250507f21ee, rel_6135ed97-cf5a-56dc-906f-bd18b9cd2022, rel_7d775267-6667-5c27-9707-f33e077a84e1, rel_c96d6a34-8b9a-5ce6-ab73-a1a38f8954a2